Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR1900 in Adult Patients With ABPA
NCT05667662Phase 2Terminated
- Sponsor
- Pulmatrix, Inc.
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of itraconazole in allergic bronchopulmonary aspergillosis (ABPA), sponsored by Pulmatrix, Inc.. Started Feb 2023; status: terminated.
02
Drugs
itraconazole
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT05667662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667662.